Vericel Corp
NASDAQ:VCEL
Intrinsic Value
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. [ Read More ]
The intrinsic value of one VCEL stock under the Base Case scenario is 35.79 USD. Compared to the current market price of 45.45 USD, Vericel Corp is Overvalued by 21%.
Valuation Backtest
Vericel Corp
Run backtest to discover the historical profit from buying and selling VCEL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vericel Corp
Current Assets | 205.6m |
Cash & Short-Term Investments | 109.6m |
Receivables | 58.4m |
Other Current Assets | 37.7m |
Non-Current Assets | 148m |
Long-Term Investments | 25.3m |
PP&E | 115.1m |
Intangibles | 6.9m |
Other Non-Current Assets | 771k |
Current Liabilities | 45.7m |
Accounts Payable | 22.3m |
Accrued Liabilities | 23.4m |
Non-Current Liabilities | 82m |
Long-Term Debt | 100k |
Other Non-Current Liabilities | 81.9m |
Earnings Waterfall
Vericel Corp
Revenue
|
197.5m
USD
|
Cost of Revenue
|
-61.9m
USD
|
Gross Profit
|
135.6m
USD
|
Operating Expenses
|
-142m
USD
|
Operating Income
|
-6.5m
USD
|
Other Expenses
|
3.3m
USD
|
Net Income
|
-3.2m
USD
|
Free Cash Flow Analysis
Vericel Corp
VCEL Profitability Score
Profitability Due Diligence
Vericel Corp's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Vericel Corp's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
VCEL Solvency Score
Solvency Due Diligence
Vericel Corp's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Vericel Corp's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VCEL Price Targets Summary
Vericel Corp
According to Wall Street analysts, the average 1-year price target for VCEL is 54.98 USD with a low forecast of 47.87 USD and a high forecast of 59.85 USD.
Ownership
VCEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VCEL Price
Vericel Corp
Average Annual Return | 17.02% |
Standard Deviation of Annual Returns | 49.44% |
Max Drawdown | -74% |
Market Capitalization | 2.2B USD |
Shares Outstanding | 48 380 500 |
Percentage of Shares Shorted | 14.57% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 281 full-time employees. The firm is focused on therapies for the sports medicine and severe burn care markets. The company markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Contact
IPO
Employees
Officers
The intrinsic value of one VCEL stock under the Base Case scenario is 35.79 USD.
Compared to the current market price of 45.45 USD, Vericel Corp is Overvalued by 21%.